靶向CD19治疗急性B淋巴细胞白血病的研究进展  

Progress of CD19-targeted therapy for acute B-lymphoblastic leukemia

作　　者：黄秀松 杨珂 谭有将 陈开明 段才闻 Huang Xiusong;Yang Ke;Tan Youjiang;Chen Kaiming;Duan Caiwen(Clinical Pathological Diagnosis and Research Center,Affiliated Hospital of Youjiang Medical University for Nationalities,Baise 533000,China;Basic Medical College,Youjiang Medical University for Nationalities,Baise 533000,China;Department of Blood Transfusion,Affiliated Hospital of Youjiang Medical University for Nationalities,Baise 533000,China;Institute of Translational Medicine,Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai200120,China)

机构地区：[1]右江民族医学院附属医院临床病理诊断与研究中心,百色533000 [2]右江民族医学院基础医学院,百色533000 [3]右江民族医学院附属医院输血科,百色533000 [4]上海交通大学医学院附属上海儿童医学中心转化所,上海200120

出　　处：《白血病．淋巴瘤》2024年第6期373-377,共5页Journal of Leukemia & Lymphoma

基　　金：广西自然科学基金(2021GXNSFAA220097);右江民族医学院研究生创新计划(YXCXJH2023015)。

摘　　要：急性B淋巴细胞白血病(B-ALL)是急性淋巴细胞白血病最常见的类型,目前治疗以化疗为主,但具有严重的不良反应。CD19普遍在B系恶性肿瘤中高表达,并在B细胞信号转导、活化以及发育等过程起关键作用,成为B细胞恶性肿瘤治疗的有效靶点之一。目前开发了多种靶向CD19的疗法,包括抗体药物偶联物、单克隆抗体、双特异性抗体和嵌合抗原受体细胞疗法等。文章就近年靶向CD19治疗B-ALL的临床试验研究进展进行综述。Acute B-lymphoblastic leukemia(B-ALL)is the most common type of acute lymphoblastic leukemia.Chemotherapy is the main treatment for most patients,but there are serious side effects.CD19 is generally highly expressed in B-lineage malignancies and plays a key role in B cell signal transduction,activation and development.Therefore,it has become one of the effective targets for treatment of B-cell malignancies.At present,a variety of therapies targeting CD19 have been developed,including antibody drug conjugates,monoclonal antibodies,bispecific antibodies and chimeric antigen receptors cell therapies.This paper reviews the clinical trial progress of CD19-targeted therapy for B-ALL.

关 键 词：CD19 急性B淋巴细胞白血病 单克隆抗体 双特异性抗体 抗体药物偶联物 嵌合抗原受体细胞 

分 类 号：R733.71[医药卫生—肿瘤]